Successful management of fetal hemolytic disease due to strong anti-Rh17 with plasma exchange and intrauterine transfusion in a woman with the D−− phenotype

2019 ◽  
Vol 111 (1) ◽  
pp. 149-154 ◽  
Author(s):  
Kazuya Mimura ◽  
Masayuki Endo ◽  
Atsushi Takahashi ◽  
Yohei Doi ◽  
Mikiko Sakuragi ◽  
...  
2014 ◽  
Vol 2 (3) ◽  
pp. 456-560 ◽  
Author(s):  
Emilija Velkova

AIM: Prompt discovery of allosensibilisation to RBC’s antigens during pregnancy and successful management of HDFN in Republic of Macedonia, in order to decrease morbidity and mortality of the fetus and the newborn.MATERIALS AND METHODS: The study comprises in total 23,800 patients, 14,858 pregnant women and 8,842 newborn babies.RESULTS: The screening and identification of anti RBC’s antibodies detected in total 216 alloantibodies, out of which 81% (175) had a clinical significance. Out of the above mentioned 164 alloantibodies (65.9%) belong to the Rh system. The most often reason for a severe hemolytic disease is the anti-D antibody. The HDFN symptoms of mild and moderate degree demonstrated 32.5%, and 18.9% had symptoms of severe fetal suffering, and almost half of them (48%) were with or with mild HDFN and had no need of therapy. In 15% it was about alloantibodies of other Rg antigens: anti-C, anti-E and anti-c, at which in most cases there were no signs of HDFN, or it showed weak symptoms (89%), just one case of anti-c ended with intrauterine death.CONCLUSIONS: Anti D antibody represents the most often reason for severe HDFN and displays a need of intrauterine transfusion and exsangvino transfusion. Anti-c is the only antibody that demonstrated the same potential for severe HBN as the anti-D. The most often reason for alloimmunisation of the mother is the lack of RhIG prophylaxis (97.8): postnatal, antenatal and in case of possible sensible conditions during pregnancy. Thus, there is a need and an outmost importance of elaboration and adoption of the National programe for RhIG prophylaxis in Republic of Macedonia.


2012 ◽  
Vol 206 (2) ◽  
pp. 141.e1-141.e8 ◽  
Author(s):  
Irene T. Lindenburg ◽  
Vivianne E. Smits-Wintjens ◽  
Jeanine M. van Klink ◽  
Esther Verduin ◽  
Inge L. van Kamp ◽  
...  

Transfusion ◽  
2013 ◽  
Vol 54 (1) ◽  
pp. 238-243 ◽  
Author(s):  
Arwa Z. Al Riyami ◽  
Moza Al Salmani ◽  
Sabria Al Hashami ◽  
Sabah Al Mahrooqi ◽  
Sumaiya Al Hinai ◽  
...  

Cureus ◽  
2017 ◽  
Author(s):  
Cyriac Philips ◽  
Rajaguru Paramaguru ◽  
Pushpa Mahadevan ◽  
Jayasurya Ravindranath ◽  
Philip Augustine

2019 ◽  
Vol 47 (3) ◽  
pp. 264-271 ◽  
Author(s):  
Slavica Dajak ◽  
Nina Ipavec ◽  
Mia Cuk ◽  
Branka Golubic Cepulic ◽  
Jela Mratinovic-Mikulandra ◽  
...  

Background: Anti-Rh17 is a rare red blood cell (RBC) antibody to high-frequency antigens that may cause severe hemolytic disease of the fetus and newborn (HDFN). Despite the rarity of HDFN caused by Anti-Rh17, this antibody was reported in many different populations. Emergency transfusions, especially exchange transfusions, present a huge problem if no compatible RBCs of phenotype D-- are available. Methods: Here we report obstetrical histories of three women and describe their pregnancies complicated by anti-Rh17 antibodies. We summarized published cases of pregnancies complicated by anti-Rh17 and reviewed transfusion treatment and outcomes. Additionally, a simplified flowchart for the management of such pregnancies is proposed. Results: Four pregnancies were affected by severe HDFN, and three of them ended with perinatal death. In the fourth case, the baby was born hydropic and icteric and the condition was rapidly deteriorating. Emergency exchange transfusion was performed with incompatible O-negative RBC units in AB-negative plasma. The baby was discharged on the 14th day in good health. In the available literature, 15 women and 22 pregnancies were reported, 20 of them developed severe HDFN. According to the data, intrauterine transfusion for treatment of HDFN was the most common form of treatment with the donation of the mother’s blood. Different options for exchange transfusion were described, including incompatible RBCs. Conclusion: In more than 90% of described pregnancies of HDFN caused by anti-Rh17 antibody, transfusion treatment was required. Therefore, RBC from D-- phenotype has to be available. According to published data, in emergent circumstances when maternal and blood from donor with phenotype D-- is not available, incompatible exchange transfusion is a better choice than delaying transfusion when it is necessary. It is of essential importance that pregnancies with high risk of HDFN due to anti-Rh17 are managed by a multidisciplinary team (transfusion medicine specialist, obstetrician, neonatologist) in a highly specialized tertiary institution.


1998 ◽  
Vol 179 (4) ◽  
pp. 858-863 ◽  
Author(s):  
Lynda Hudon ◽  
Kenneth J. Moise ◽  
Suzanne E. Hegemier ◽  
Reba M. Hill ◽  
Alicia A. Moise ◽  
...  

2015 ◽  
Vol 53 (3) ◽  
pp. 399-402 ◽  
Author(s):  
Brett L. Houston ◽  
Rachelle Govia ◽  
Ahmed M. Abou-Setta ◽  
Gregory J. Reid ◽  
Marie Hadfield ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document